AGPAT2

Across TCGA pan-cancer cohorts, AGPAT2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of AGPAT2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where AGPAT2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types AGPAT2 is over-expressed in tumor, although a few such as LUSC and BRCA show the opposite, repressed pattern.

BLCA, LUSC, and THCA are the cancer types where AGPAT2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AGPAT2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	+0.916	.001	8	view →
LUSC	Male	All	−0.989	<.001	7	view →
THCA	Male	All	+0.615	<.001	7	view →
BRCA	All	II,III,IV	−1.333	<.001	6	view →
KIRC	All	All	−0.365	.003	6	view →
LIHC	Male	All	−0.829	<.001	5	view →
HNSC	Male	All	+0.539	.001	5	view →
STAD	All	II,III,IV	+1.225	.001	4	view →
LUAD	All	All	−0.505	<.001	4	view →
ESCA	All	All	+2.001	<.001	3	view →
UCEC	All	All	+1.092	<.001	2	view →
KICH	Male	All	−0.881	.008	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

AGPAT2–BLCA

Open the BLCA breakdown →